Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
25 Apr 24
EFFECT
Notice of effectiveness
23 Apr 24
DEF 14A
Definitive proxy
17 Apr 24
8-K/A
Other Events
3 Apr 24
8-K
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
26 Mar 24
DEF 14A
Definitive proxy
20 Mar 24
S-1/A
IPO registration (amended)
19 Mar 24
8-K
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
15 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
S-1
IPO registration
8 Mar 24
PRE 14A
Preliminary proxy
8 Mar 24
D
$8.00 mm in equity / options / securities to be acquired, sold $8.00 mm, 8 investors
5 Mar 24
8-K
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
23 Feb 24
8-K
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
20 Feb 24
RW
Registration withdrawal request
20 Feb 24
8-K
Other Events
12 Feb 24
8-K
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for AmeluzĀ® to Permit Up to Three Tubes per Use
5 Feb 24
8-K
Entry into a Material Definitive Agreement
2 Feb 24
S-1/A
IPO registration (amended)
29 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Jan 24
S-1
IPO registration
16 Jan 24
8-K
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
11 Jan 24
8-K/A
Termination of a Material Definitive Agreement
9 Jan 24
8-K
Entry into a Material Definitive Agreement
3 Jan 24
8-K
Entry into a Material Definitive Agreement
28 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
27 Dec 23
8-K
Entry into a Material Definitive Agreement
15 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Nov 23
DEF 14A
Definitive proxy
17 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
9 Nov 23
8-K
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
2 Nov 23
424B4
Prospectus supplement with pricing info
1 Nov 23
EFFECT
Notice of effectiveness
31 Oct 23
CORRESP
Correspondence with SEC
27 Oct 23
S-1/A
IPO registration (amended)
26 Oct 23
S-1/A
IPO registration (amended)
13 Oct 23
8-K
Entry into a Material Definitive Agreement
13 Oct 23
CORRESP
Correspondence with SEC
13 Oct 23
UPLOAD
Letter from SEC
11 Oct 23
Latest ownership filings
SC 13G
Rosalind Advisors, Inc.
21 Mar 24
SC 13G
Rosalind Advisors, Inc.
20 Mar 24
SC 13G
LYTTON LAURENCE W
20 Mar 24
SC 13G
HIRSCHMAN ORIN
20 Mar 24
SC 13G
Bigger Capital, LLC
15 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
3
Heikki Lanckriet
22 Aug 23
4
Erica L. Monaco
22 May 23
4
Hermann Luebbert
22 May 23
4
Eugene Frederick Leffler
12 Jan 23
4
Erica F. Gates
12 Jan 23
3
Eugene Frederick Leffler
4 Nov 22
SC 13G
Abshagen Consulting GmbH
4 Nov 22
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
19 Sep 22
4
Erica L. Monaco
19 Sep 22
4
Hermann Luebbert
19 Sep 22
SC 13D
DEUTSCHE BALATON AKTIENGESELLSCHAFT
25 Aug 22
4/A
Loretta M. Wedge
6 Jun 22
4/A
Kevin Daniel Weber
6 Jun 22
4/A
JOHN J BORER III
6 Jun 22
4/A
Beth J. Hoffman
6 Jun 22
4
Erica F. Gates
26 May 22
4
Erica L. Monaco
26 May 22
4
Beth J. Hoffman
26 May 22
4
Hermann Luebbert
26 May 22
4
JOHN J BORER III
26 May 22
4
Loretta M. Wedge
26 May 22
4
Kevin Daniel Weber
26 May 22
3
Kevin Daniel Weber
14 Mar 22
SC 13G
Biofrontera AG
10 Feb 22
4/A
Erica L. Monaco
19 Jan 22
4/A
Erica F. Gates
19 Jan 22
4
Hermann Luebbert
19 Jan 22
4
Erica L. Monaco
13 Dec 21
4
Erica F. Gates
13 Dec 21
3
Loretta M. Wedge
2 Nov 21
3
JOHN J BORER III
2 Nov 21
3
Beth J. Hoffman
2 Nov 21
3
AG Biofrontera
28 Oct 21
3
Hermann Luebbert
28 Oct 21